Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone.

Kashiwagi Y, Mizuno Y, Harada E, Shono M, Morita S, Yoshimura M, Yano M, Yasue H.

Am J Med Sci. 2013 Jun;345(6):497-500. doi: 10.1097/MAJ.0b013e31827ad893.

PMID:
23313950
[PubMed - indexed for MEDLINE]
2.

Normokalemic hyperaldosteronism in patients with resistant hypertension.

Benchetrit S, Bernheim J, Podjarny E.

Isr Med Assoc J. 2002 Jan;4(1):17-20.

PMID:
11802302
[PubMed - indexed for MEDLINE]
Free Article
3.

[Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].

Szücs N, Gláz E, Varga I, Tóth M, Kiss R, Patócs A, Jakab C, Perner F, Járay J, Horányi J, Dabasi G, Molnár F, Major L, Füto L, Rácz K, Tulassay Z.

Orv Hetil. 2006 Jan 15;147(2):51-9. Hungarian.

PMID:
16509213
[PubMed - indexed for MEDLINE]
4.

Diagnostic value of the post-captopril test in primary aldosteronism.

Castro OL, Yu X, Kem DC.

Hypertension. 2002 Apr;39(4):935-8.

PMID:
11967253
[PubMed - indexed for MEDLINE]
Free Article
5.

Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.

Yoneda T, Demura M, Takata H, Kometani M, Karashima S, Yamagishi M, Takeda Y.

J Clin Endocrinol Metab. 2012 Apr;97(4):1109-13. doi: 10.1210/jc.2011-2563. Epub 2012 Feb 15.

PMID:
22337911
[PubMed - indexed for MEDLINE]
6.

[High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension].

Mosso L, Fardella C, Montero J, Rojas P, Sánchez O, Rojas V, Rojas A, Huete A, Soto J, Foradori A.

Rev Med Chil. 1999 Jul;127(7):800-6. Spanish.

PMID:
10668287
[PubMed - indexed for MEDLINE]
7.

Primary aldosteronism: A common and curable form of hypertension.

Young WF Jr.

Cardiol Rev. 1999 Jul-Aug;7(4):207-14. Review.

PMID:
10423672
[PubMed - indexed for MEDLINE]
8.

[Detection of primary aldosteronism using the captopril test].

Pirich K, Vierhapper H, Graninger W, Nowotny P, Waldhäusl W.

Wien Klin Wochenschr. 1987 Sep 11;99(17):608-11. German.

PMID:
3314169
[PubMed - indexed for MEDLINE]
9.

Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties.

Brzozowski T, Konturek PC, Pajdo R, Kwiecień SN, Konturek S, Targosz A, Burnat G, Cieszkowski J, Pawlik WW, Hahn EG.

Inflammopharmacology. 2005;13(1-3):317-30.

PMID:
16259750
[PubMed - indexed for MEDLINE]
10.

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J.

J Am Coll Cardiol. 2008 Sep 2;52(10):869-81. doi: 10.1016/j.jacc.2008.04.055. Epub 2008 Jul 2.

PMID:
18755353
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Primary aldosteronism: diagnostic and treatment strategies.

Mattsson C, Young WF Jr.

Nat Clin Pract Nephrol. 2006 Apr;2(4):198-208; quiz, 1 p following 230. Review.

PMID:
16932426
[PubMed - indexed for MEDLINE]
12.

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.

PMID:
17520238
[PubMed - indexed for MEDLINE]
13.

Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.

Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC.

Metabolism. 2010 Aug;59(8):1139-44. doi: 10.1016/j.metabol.2009.10.030. Epub 2009 Dec 31.

PMID:
20045142
[PubMed - indexed for MEDLINE]
14.

High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.

Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F.

Am J Hypertens. 2002 Oct;15(10 Pt 1):896-902.

PMID:
12372677
[PubMed - indexed for MEDLINE]
15.

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M.

Lancet. 2009 Jul 11;374(9684):126-35. doi: 10.1016/S0140-6736(09)60870-9. Epub 2009 Jun 8.

PMID:
19515415
[PubMed - indexed for MEDLINE]
16.

[A case of idiopathic hyperaldosteronism with normal plasma aldosterone concentrations for 5 years after onset: a 12-year follow-up study].

Nemoto T, Niimura S, Hayashi A, Gomibuchi T, Sanada H, Watanabe Y, Shigetomi S, Fukuchi S.

Nihon Naibunpi Gakkai Zasshi. 1994 May 20;70(4):439-46. Japanese.

PMID:
7958093
[PubMed - indexed for MEDLINE]
17.
18.

Primary aldosteronism: renaissance of a syndrome.

Young WF.

Clin Endocrinol (Oxf). 2007 May;66(5):607-18. Review.

PMID:
17492946
[PubMed - indexed for MEDLINE]
19.

Detecting and treating primary aldosteronism: primary aldosteronism.

Mantero F, Mattarello MJ, Albiger NM.

Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):171-4. Review.

PMID:
17427105
[PubMed - indexed for MEDLINE]
20.

Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.

Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

Diabet Med. 2010 Feb;27(2):150-6. doi: 10.1111/j.1464-5491.2009.02906.x.

PMID:
20546257
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk